13-amino-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione | 151069-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 13-amino-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
• CAS: 151069-56-6
• 化学式: C₂₆H₂₂N₄O₉
• 分子量: 534.482
• InChiKey: VEYAIEJPIPPMJW-QCUUGYDUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  39
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  215
• 氢给体数：
  8
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  13-amino-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione 、 1H-吡唑-3-甲醛 在 溶剂黄146 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE WITH ANTITUMOR ACTIVITY

  摘要：

  本发明涉及一种新颖的吲哚吡咯咯嗪衍生物，其由以下式[I]表示：其中：A代表O、NH或CH2；R1代表单键、较低的烷基、较低的烯基、较低的炔基等；R2代表苯基、萘基或含有N、S或O中至少一个原子的五元或六元芳香或脂环，其中苯基、萘基、芳香或脂环可以被取代；G代表己糖基或戊糖基，或其药用可接受的盐。

  公开号：

  EP1666485A1

文献信息

• Indolopyrrolocarbazole derivatives and antitumor agents
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US06703373B1

  公开（公告）日：2004-03-09

  A compound represented by the formula or a pharmaceutically acceptable salt thereof wherein R represents an unsubstituted pyridyl, furyl or thienyl group, or a pyridyl, furyl or thienyl group each of which has one or more substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group except that when the pyridyl, furyl or thienyl group has a lower alkoxy group as a substituent, each of which simultaneously has another substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group, m represents an integer of 1 to 3, and G represents a &bgr;-D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 1- and 11-positions, or the 2- and 10-positions, and an antitumore agent containing it as an effective ingredient. The compounds have a better antitumor action than known compounds having a similar structure.

  化合物的化学式为或其药学上可接受的盐，其中R代表未取代的吡啶基，呋喃基或噻吩基，或者是带有一个或多个取代基的吡啶基，呋喃基或噻吩基，所述取代基选自羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团的群，但是当吡啶基，呋喃基或噻吩基带有较低的烷氧基取代基时，每个取代基同时具有羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团中的另一个取代基时，m表示1到3的整数，G表示β-D-葡萄糖吡喃糖基，并且羟基取代在吲哚吡咯喹啉环上的位置为1-和11-位置，或2-和10-位置，以及含有其作为有效成分的抗肿瘤剂。这些化合物比具有类似结构的已知化合物具有更好的抗肿瘤作用。
• Synthesis and Biological Activities of Topoisomerase I Inhibitors, 6-Arylmethylamino Analogues of Edotecarin
  作者：Satoshi Sunami、Teruyuki Nishimura、Ikuko Nishimura、Satoru Ito、Hiroharu Arakawa、Mitsuru Ohkubo

  DOI：10.1021/jm801641t

  日期：2009.5.28

  The replacement of 1,3-dihydroxy-2-propylamino moiety at the N6-position of edotecarin (1) by arylmethylamino groups yielded a number of more potent topoisomerase I inhibitors with better cytotoxic (CTX) activities in vitro than edotecarin. Among them, the three most potent pyridylmethyl analogues, compounds 22g, 22m, and 23c, showed better antitumor activities against MKN-45 human stomach cancer or MX-1 human breast cancer xenografted mice than those of edotecarin. Furthermore, compounds 22m and 23c exhibited complete response against MX-1 cells implanted in mice.
• EP1652854
  申请人：——

  公开号：——

  公开（公告）日：——
• EP1652853
  申请人：——

  公开号：——

  公开（公告）日：——
• NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE WITH ANTITUMOR ACTIVITY
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1666485A1

  公开（公告）日：2006-06-07

  The present invention relates to a novel indolopyrrolocarbazole derivative which is represented by the formula [I]: wherein: A represents O, NH, or CH2; R1 represents a single bond, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, etc.; R2 represents a phenyl group, a naphthyl group, or a five- or six-membered aromatic or aliphatic heterocyclic ring having at least one atom selected from N, S, or O, wherein the phenyl group, naphthyl group, aromatic or aliphatic heterocyclic ring may be substituted; and G represents a hexose group or a pentose group, or a pharmaceutically acceptable salt thereof

  本发明涉及一种新颖的吲哚吡咯咯嗪衍生物，其由以下式[I]表示：其中：A代表O、NH或CH2；R1代表单键、较低的烷基、较低的烯基、较低的炔基等；R2代表苯基、萘基或含有N、S或O中至少一个原子的五元或六元芳香或脂环，其中苯基、萘基、芳香或脂环可以被取代；G代表己糖基或戊糖基，或其药用可接受的盐。